Key result
Inhibition of the m6A mRNA demethylase FTO significantly suppressed VEGFA release and choroidal neovascularization in a mouse model of laser-induced injury.
This is the authors' abstract. We don't add key points for this paper.
Vascular endothelial growth factor-A (VEGFA, also known as VEGF) is a critical angiogenic factor that regulates the physiological and pathological blood vessel growth. 1 Increased abundance of VEGF in the eye underlies many forms of aberrant ocular angiogenesis and resultant vision loss, including in neovascular age-related macular degeneration (nvAMD), proliferative diabetic retinopathy (PDR), ischemic retinal vein occlusion, and retinopathy of prematurity (ROP). Multiple VEGF inhibitors are approved for such ocular angiogenic diseases. Despite the initial, and often dramatic, efficacy of anti-VEGF therapy, real-world and long-term studies are more sobering. 2 , 3 Thus, enhanced understanding about the regulation of ocular VEGF can further elucidate the underlying pathological mechanisms and aid in developing new therapeutic strategies.
May identify FTO as an anti-angiogenic target; leaves open translation to human choroidal neovascularization.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted a letter in Choroidal neovascularization. FTO inhibitor vs. Vehicle was evaluated on Choroidal neovascularization and VEGFA release. Inhibition of the m6A mRNA demethylase FTO significantly suppressed VEGFA release and choroidal neovascularization in a mouse model of laser-induced injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: